Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%...

Related Keywords

Stockholm ,Sweden ,Hungary ,Budapest ,Viktor Drvota ,Johan Dighed ,Karolinska Institutet ,Investment Fund ,Buda Health Clinic ,Drug Administration ,National Center ,Karolinska Development ,Karolinska Development Ab Nasdaq Stockholm ,Nasdaq Stockholm ,Ossdsign Catalyst ,Spinal Disorders ,Dsign Catalyst ,Nasdaq First North Growth Market ,General Counsel ,